Role of glutathione in immunity and inflammation in the lung

International Journal of General Medicine

Volumn 4, Issue , 2011, Pages 105-113

  Ghezzi, Pietro ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antioxidants; Cysteine; Infection; Oxidative stress; Sepsis

Indexed keywords

GLUTATHIONE; GLUTATHIONE SYNTHASE; REACTIVE OXYGEN METABOLITE; SCAVENGER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; DEFENSE MECHANISM; ENZYME DEFICIENCY; GLUTATHIONE METABOLISM; GLUTATHIONE SYNTHASE DEFICIENCY; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; INFLUENZA; INNATE IMMUNITY; MEMBRANE DAMAGE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PNEUMONIA; PROTEIN FUNCTION; REVIEW; SEPSIS; TUBERCULOSIS;

EID: 84897367571     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S15618     Document Type: Review

References (89)

1. Dormandy TL. Biological rancidification. Lancet. 1969;2(7622): 684-688.
2. Tappel A, Zalkin H. Inhibition of lipid peroxidation in microsomes by vitamin E. Nature. 1960;185:35.
3. Lyons J, Rauh-Pfeiffer A, Ming-Yu Y, et al. Cysteine metabolism and whole blood glutathione synthesis in septic pediatric patients. Crit Care Med. 2001;29(4):870-877.
4. Biolo G, Antonione R, De Cicco M. Glutathione metabolism in sepsis. Crit Care Med. 2007;35(9 Suppl):S591-S595.
5. Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis. 2007;2:16.
6. Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr. 2001;139(1): 79-84.
7. Spielberg SP, Boxer LA, Oliver JM, Allen JM, Schulman JD. Oxidative damage to neutrophils in glutathione synthetase deficiency. Br J Haematol. 1979;42(2):215-223.
8. Boxer LA, Oliver JM, Spielberg SP, Allen JM, Schulman JD. Protection of granulocytes by vitamin E in glutathione synthetase deficiency. N Engl J Med. 1979;301(17):901-905.
9. Jackson AA, Gibson NR, Lu Y, Jahoor F. Synthesis of erythrocyte glutathione in healthy adults consuming the safe amount of dietary protein. Am J Clin Nutr. 2004;80(1):101-107.
10. Martin JA, Sastre J, de la Asuncion JG, Pallardo FV, Vina J. Hepatic gamma-cystathionase deficiency in patients with AIDS. JAMA. 2001; 285(11):1444-1445.
11. Malmezat T, Breuille D, Capitan P, Mirand PP, Obled C. Glutathione turnover is increased during the acute phase of sepsis in rats. J Nutr. 2000;130(5):1239-1246.
12. Malmezat T, Breuille D, Pouyet C, et al. Methionine transsulfuration is increased during sepsis in rats. Am J Physiol Endocrinol Metab. 2000; 279(6):E1391-E1397.
13. Hunter EA, Grimble RF. Cysteine and methionine supplementation modulate the effect of tumor necrosis factor alpha on protein synthesis, glutathione and zinc concentration of liver and lung in rats fed a low protein diet. J Nutr. 1994;124(12):2319-2328.
14. Hunter EA, Grimble RF. Dietary sulphur amino acid adequacy influences glutathione synthesis and glutathione-dependent enzymes during the inflammatory response to endotoxin and tumour necrosis factor-alpha in rats. Clin Sci (Lond). 1997;92(3):297-305.
15. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. Embo J. 1991;10(8):2247-2258.
16. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141-179.
17. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol. 1996;157(4): 1630-1637.
18. Kloek J, Van Ark I, De Clerck F, Bloksma N, Nijkamp FP, Folkerts G. Modulation of airway hyperresponsiveness by thiols in a murine in vivo model of allergic asthma. Inflamm Res. 2003;52(3):126-131.
19. Lee YC, Lee KS, Park SJ, et al. Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid. FASEB J. 2004;18(15): 1917-1919.
20. Cuzzocrea S, Mazzon E, Dugo L, et al. Protective effects of N-acetylcysteine on lung injury and red blood cell modification induced by carrageenan in the rat. FASEB J. 2001;15(7):1187-1200.
21. Lailey AF, Hill L, Lawston IW, Stanton D, Upshall DG. Protection by cysteine esters against chemically induced pulmonary oedema. Biochem Pharmacol. 1991;42 Suppl:S47-S54.
22. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229-2242.
23. Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med. 2000;162(1):225-231.
24. Afaq F, Abidi P, Rahman Q. N-acetyl L-cysteine attenuates oxidantmediated toxicity induced by chrysotile fibers. Toxicol Lett. 2000; 117(1-2):53-60.
25. Rhoden CR, Lawrence J, Godleski JJ, Gonzalez-Flecha B. N-acetylcysteine prevents lung inflammation after short-term inhalation exposure to concentrated ambient particles. Toxicol Sci. 2004;79(2): 296-303.
26. Langley SC, Kelly FJ. N-acetylcysteine ameliorates hyperoxic lung injury in the preterm guinea pig. Biochem Pharmacol. 1993;45(4): 841-846.
27. Levy MA, Sikorski B, Bray TM. Selective elevation of glutathione levels in target tissues with L-2-oxothiazolidine-4-carboxylate (OTC) protects against hyperoxia-induced lung damage in protein-energy malnourished rats: implications for a new treatment strategy. J Nutr. 1998;128(4):671-676.
28. Lucas MC, Ludena MD, Barbero EA, Sanchez-Gascon F. Effects of N-acetylcysteine on hyperoxic lung in the rat. Respir Med. 1995; 89(4):311.
29. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006;103(12): 4628-4633.
30. Hodge S, Matthews G, Mukaro V, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function is improved by treatment with procysteine. Am J Respir Cell Mol Biol. Jul 1. [Epub ahead of print].
31. Park EM, Park YM, Gwak YS. Oxidative damage in tissues of rats exposed to cigarette smoke. Free Radic Biol Med. 1998;25(1):79-86.
32. Cuzzocrea S, Costantino G, Zingarelli B, Mazzon E, Micali A, Caputi AP. The protective role of endogenous glutathione in carrageenan- induced pleurisy in the rat. Eur J Pharmacol. 1999;372(2):187-197.
33. Haddad JJ. L-Buthionine-(S,R)-sulfoximine, an irreversible inhibitor of gamma-glutamylcysteine synthetase, augments LPS-mediated proinflammatory cytokine biosynthesis: evidence for the implication of an IkappaB-alpha/NF-kappaB insensitive pathway. Eur Cytokine Netw. 2001;12(4):614-624.
34. Thimmulappa RK, Lee H, Rangasamy T, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 2006;116(4):984-995.
35. Moinova HR, Mulcahy RT. Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun. 1999;261(3):661-668.
36. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1989;139(2):370-372.
37. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J. 1994;7(3):431-436.
38. Sido B, Braunstein J, Breitkreutz R, Herfarth C, Meuer SC. Thiolmediated redox regulation of intestinal lamina propria T lymphocytes. J Exp Med. 2000;192(6):907-912.
39. Hadzic T, Li L, Cheng N, Walsh SA, Spitz DR, Knudson CM. The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion. J Immunol. 2005;175(12):7965-7972.
40. Oliver JM, Albertini DF, Berlin RD. Effects of glutathione-oxidizing agents on microtubule assembly and microtubule-dependent surface properties of human neutrophils. J Cell Biol. 1976;71(3):921-932.
41. Kuppner MC, Scharner A, Milani V, et al. Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion. Blood. 2003;102(10):3668-3674.
42. Arunachalam B, Phan UT, Geuze HJ, Cresswell P. Enzymatic reduction of disulf ide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc Natl Acad Sci U S A. 2000;97(2):745-750.
43. Short S, Merkel BJ, Caffrey R, McCoy KL. Defective antigen processing correlates with a low level of intracellular glutathione. Eur J Immunol. 1996;26(12):3015-3020.
44. Murata Y, Ohteki T, Koyasu S, Hamuro J. IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol. 2002;32(10):2866-2873.
45. Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology, 6th Edition. New York - London: Garland Science; 2005.
46. Parameswaran GI, Murphy TF. Infections in chronic lung diseases. Infect Dis Clin North Am. 2007;21(3):673-695, viii.
47. Sorensen RU, Waller RL, Klinger JD. Cystic fibrosis. Infection and immunity to Pseudomonas. Clin Rev Allergy. 1991;9(1-2):47-74.
48. Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J Immunol. 2001; 166(12):7410-7418.
49. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun. 2006;74(12):6707-6721.
50. Brown LA, Harris FL, Ping XD, Gauthier TW. Chronic ethanol ingestion and the risk of acute lung injury: a role for glutathione availability? Alcohol. 2004;33(3):191-197.
51. Nelson S, Kolls JK. Alcohol, host defence and society. Nat Rev Immunol. 2002;2(3):205-209.
52. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998;95(6):3071-3076.
53. Suliman HB, Ryan LK, Bishop L, Folz RJ. Prevention of influenzainduced lung injury in mice overexpressing extracellular superoxide dismutase. Am J Physiol Lung Cell Mol Physiol. 2001;280(1): L69-L78.
54. Akaike T, Ando M, Oda T, et al. Dependence on O2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Invest. 1990;85(3):739-745.
55. McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem. 1968;243(21):5753-5760.
56. Wang JP, Bowen GN, Padden C, et al. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood. 2008;112(5): 2028-2034.
57. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203-1207.
58. Kumar P, Sharma S, Khanna M, Raj HG. Effect of Quercetin on lipid peroxidation and changes in lung morphology in experimental influenza virus infection. Int J Exp Pathol. 2003;84(3):127-133.
59. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science. 1989;244(4907):974-976.
60. Nakamura H, Tamura S, Watanabe I, Iwasaki T, Yodoi J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol Lett. 2002;82(1-2):165-170.
61. Ungheri D, Pisani C, Sanson G, et al. Protective effect of N-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol. 2000;13(3):123-128.
62. Ghezzi P, Ungheri D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol. 2004;17(1):99-102.
63. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol. 2007;20(2): 349-354.
64. Cai J, Chen Y, Seth S, Furukawa S, Compans RW, Jones DP. Inhibition of influenza infection by glutathione. Free Radic Biol Med. 2003;34(7): 928-936.
65. Lazrak A, Iles KE, Liu G, Noah DL, Noah JW, Matalon S. Influenza virus M2 protein inhibits epithelial sodium channels by increasing reactive oxygen species. FASEB J. 2009;23(11):3829-3842.
66. Nencioni L, Iuvara A, Aquilano K, et al. Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2. FASEB J. 2003;17(6):758-760.
67. Eck HP, Gmunder H, Hartmann M, Petzoldt D, Daniel V, Droge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler. 1989;370(2): 101-108.
68. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997;94(5):1967-1972.
69. Garaci E, Palamara AT, Ciriolo MR, et al. Intracellular GSH content and HIV replication in human macrophages. J Leukoc Biol. 1997;62(1): 54-59.
70. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA. Cytokinestimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A. 1990;87(12): 4884-4888.
71. Pu H, Tian J, Andras IE, et al. HIV-1 Tat protein-induced alterations of ZO-1 expression are mediated by redox-regulated ERK 1/2 activation. J Cereb Blood Flow Metab. 2005;25(10):1325-1335.
72. Visalli V, Muscoli C, Sacco I, et al. N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction. BMC Neurosci. 2007;8:106.
73. Venketaraman V, Dayaram YK, Amin AG, et al. Role of glutathione in macrophage control of mycobacteria. Infect Immun. 2003;71(4): 1864-1871.
74. Venketaraman V, Dayaram YK, Talaue MT, Connell ND. Glutathione and nitrosoglutathione in macrophage defense against Mycobacterium tuberculosis. Infect Immun. 2005;73(3):1886-1889.
75. Garg S, Vitvitsky V, Gendelman HE, Banerjee R. Monocyte differentiation, activation, and mycobacterial killing are linked to transsulfuration- dependent redox metabolism. J Biol Chem. 2006; 281(50): 38712-38720.
76. Venketaraman V, Millman A, Salman M, et al. Glutathione levels and immune responses in tuberculosis patients. Microb Pathog. 2008;44(3): 255-261.
77. Green RM, Seth A, Connell ND. A peptide permease mutant of Mycobacterium bovis BCG resistant to the toxic peptides glutathione and S-nitrosoglutathione. Infect Immun. 2000;68(2):429-436.
78. Connell ND, Venketaraman V. Control of mycobacterium tuberculosis infection by glutathione. Recent Pat Antiinfect Drug Discov. 2009;4(3): 214-226.
79. Buchmuller-Rouiller Y, Corrandin SB, Smith J, et al. Role of glutathione in macrophage activation: effect of cellular glutathione depletion on nitrite production and leishmanicidal activity. Cell Immunol. 1995; 164(1):73-80.
80. Davreux CJ, Soric I, Nathens AB, et al. N-acetyl cysteine attenuates acute lung injury in the rat. Shock. 1997;8(6):432-438.
81. Gatti S, Faggioni R, Echtenacher B, Ghezzi P. Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide-induced pulmonary oedema and lethality. Clin Exp Immunol. 1993;91(3): 456-461.
82. Bernard GR, Lucht WD, Niedermeyer ME, Snapper JR, Ogletree ML, Brigham KL. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest. 1984;73(6):1772-1784.
83. ACCP. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.
84. Bone RC. Sepsis and its complications: the clinical problem. Crit Care Med. 1994;22(7):S8-S11.
85. Redl H, Schlag G, Bahrami S, Yao YM. Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. World J Surg. 1996;20(4):487-492.
86. Villa P, Saccani A, Sica A, Ghezzi P. Glutathione protects mice from lethal sepsis by limiting inflammation and potentiating host defense. J Infect Dis. 2002;185(8):1115-1120.
87. Ghezzi P, Di Simplicio P. Glutathionylation pathways in drug response. Curr Opin Pharmacol. 2007;7(4):398-403.
88. Ghezzi P. Oxidoreduction of protein thiols in redox regulation. Biochem Soc Trans. 2005;33(Pt 6):1378-1381.
89. Ghezzi P. Regulation of protein function by glutathionylation. Free Radic Res. 2005;39(6):573-580.